Vildagluse Plus 50/500 mg Type 2 Diabetes Management - 30 Film Coated Tablets

Optimize your blood glucose control with Vildagluse Plus 50/500 mg Film Coated Tablets (30 Tablets). Formulated by Inspira Pharma, this advanced dual-action prescription medication combines 50 mg of Vildagliptin (a DPP-4 inhibitor) with 500 mg of Metformin Hydrochloride (a biguanide). Together, they work symmetrically to enhance pancreatic insulin secretion, reduce hepatic glucose production, and improve peripheral insulin sensitivity. Designed for adults diagnosed with Type 2 Diabetes Mellitus, it serves as a highly effective therapy when lifestyle changes alone are insufficient. Each box contains 30 film-coated tablets for a complete monthly treatment cycle.

Dual-Action Glycemic Control: Combines Vildagliptin (50 mg) and Metformin HCl (500 mg) to target multiple pathways of blood sugar regulation.
Enhanced Insulin Response: Vildagliptin actively stimulates the pancreas to produce more insulin while lowering glucagon secretion.
Reduces Glucose Production: Metformin lowers the amount of sugar manufactured by the liver and improves cellular insulin sensitivity.
Convenient Monthly Pack: Contains 30 premium film-coated tablets, structured perfectly to align with a standard 30-day prescription.
Inspira Pharma Quality: Manufactured under rigorous pharmaceutical standards to ensure high bio-availability and ingredient purity.

EGP 135EGP 145

In Stock

Delivery to governorates within 3-4 working days

Easy returns within 14 days

Specifications

SKU	ISG016518
Color	Luscious Blackberry
UPC	6224000866860

About the product›

Vildagluse Plus 50/500 mg Tablets – Dual-Action Prescription Therapy for Type 2 Diabetes

Take structured, proactive control of your glycemic health with Vildagluse Plus 50/500 mg Film Coated Tablets. Produced by Inspira Pharma, this premium prescription medication is scientifically engineered to assist adults with Type 2 Diabetes Mellitus in achieving and maintaining their target $HbA1c$ levels. By pairing two distinct, clinically trusted anti-diabetic agents into a single daily tablet, Vildagluse Plus simplifies your medical routine while maximizing metabolic control.

As illustrated on the product packaging in 14b1bbe1-95c2-44c0-a868-23b12485c701.jpeg, each tablet contains a balanced ratio of Vildagliptin (50 mg) and Metformin HCl (500 mg). Vildagliptin functions by preventing the breakdown of incretin hormones, which safely prompts the pancreas to secrete insulin when blood sugar levels are elevated. Simultaneously, Metformin enhances the way your body processes insulin, decreasing intestinal absorption of glucose and preventing the liver from releasing excessive sugar stores into the bloodstream.

Key Therapeutic Benefits & Clinical Highlights:

Comprehensive Sugar Regulation: Effectively reduces both fasting and postprandial (post-meal) blood glucose levels.
Synergistic Mechanism: Minimizes the risk of hypoglycemia (dangerously low blood sugar) compared to traditional sulfonylureas when used correctly.
Weight-Neutral Profile: Metformin therapy is clinically recognized for being weight-neutral or assisting with mild weight management.
Optimized Compliance: Consolidating two medications into one oral film-coated tablet reduces pill burden and improves patient adherence.

Directions for Safe and Accurate Administration:

Vildagluse Plus must be taken strictly according to the dosing schedule prescribed by your endocrinologist or physician. The standard clinical recommendation is to swallow the tablet whole with a glass of water during or immediately after a meal to reduce potential gastrointestinal upset. Do not split, crush, or chew the tablets. For optimal results, combine this medication with a balanced, low-glycemic diet and a regular exercise regimen as guided by your healthcare provider.